Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ritlecitinib - Pfizer

Next Previous
Drug Profile

Ritlecitinib - Pfizer

Alternative Names: LITFULO; Litfulo; PF 06651600; PF 6651600; Ritlecitinib tosilate - Pfizer; Ritlecitinib tosylate - Pfizer

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer National Institute of Diabetes and Digestive and Kidney Diseases; Pfizer
  • Class Amines; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Antiulcers; Heterocyclic bicyclo compounds; Ketones; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia areata
  • Phase III Ulcerative colitis; Vitiligo
  • Phase II Coeliac disease; Crohn's disease; Type 1 diabetes mellitus
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2025 Phase-III clinical trials in Alopecia areata (In children, Treatment-experienced) in Japan, USA (PO) (NCT07029711)
  • 15 Jul 2025 Pfizer terminates a phase II trial in Cutaneous T Cell Lymphomas in USA, due to no significant improvement in the disease as graded by the assessments (NCT05879458)
  • 19 Jun 2025 Pfizer plans a phase III trial for Alopecia areata (In Children) in July 2025 (PO) (NCT07029828)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top